Citations

Clear

5 citation(s) found for "Louissaint, Abner".

Genomic and transcriptomic landscape of extranodal marginal zone lymphoma
Lossos, Izidore S., Biral, Leo, Thakkar, Devang, Naresh, Kikkeri N, Ondrejka, Sarah, Hsi, Eric, Xu, Mina, Koff, Jean, Jaye, David, Nørgaard, Peter, Breinholt, Marie Fredslund, Leeman-Neill, Rebecca, Shingleton, Jennifer, Happ, Lanie, Love, Cassandra, Mason, Emily F., Louissaint, Abner, Ong, Choon Kiat, Cheng, Chee Leong, Pillai, Raju, Pedersen, Mette, Yin, C. Cameron, Au-Yeung, Rex, Karjalainen-Lindsberg, Marja-Liisa, Chadburn, Amy, McKinney, Matthew, Sojitra, Payal, Evans, Andrew, Czader, Magdalena, Jiong, Yan, Dave, Sandeep, Chapman, Jennifer, Lossos, Izidore S., Biral, Leonardo P. A. , Thakkar, Devang, Naresh, Kikkeri N, Ondrejka, Sarah, Hsi, Eric, Xu, Mina, Koff, Jean, Jaye, David, Nørgaard, Peter, Breinholt, Marie Fredslund, Leeman-Neill, Rebecca, Shingleton, Jennifer, Happ, Lanie, Love, Cassandra, Mason, Emily F., Louissaint, Abner, Ong, Choon Kiat, Cheng, Chee Leong, Pillai, Raju, Pedersen, Mette, Yin, C. Cameron, Au-Yeung, Rex, Karjalainen-Lindsberg, Marja-Liisa, Chadburn, Amy, McKinney, Matthew, Sojitra, Payal, Evans, Andrew, Czader, Magdalena, Jiong, Yan, Dave, Sandeep, Chapman, Jennifer

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1761-1761

10.1182/blood-2025-1761 Get It

Abstract Marginal zone lymphoma (MZL) is an uncommon non-Hodgkin B-cell lymphoma accounting for 7-10% of lymphoma diagnoses. Extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT) is the most common subtype (61%) of MZL. While the mutational landscape, chromosomal aberrations and transcriptome of nodal and splenic MZL have been extensively evaluated, the mutational landscape of EMZL has only been evaluated in a small number of patients and mainly by targeted sequencing. Consequently, the comprehensive genomic landscape of EMZL remains largely uncharacterized. Herein, we performed whole exome sequencing followed by targeted sequencing of potential tumor driver genes, copy number and/or RNA transcriptome analyses in 165 patients with pretreatment EMZL tumors involving 16 anatomic locations. All samples were collected and underwent expert review as part of the Atlas of Blood Cancer Genomes consortium. The most common anatomic locations were ocular adnexa (OAMZL) (n=35), gastric (n=25, including 6 positive for Helicobacter pylori), salivary glands (n=25), and lungs (n=24). Using common criteria for variant mutation calling and significant focal copy number (CN), we identified 1218 variants (1030 missense and 188 truncation mutations) across 174 genes and 2837 CN focal alterations (1614 copy gains and 1223 copy number losses). Of these genes, 44 and 11 were mutated in >5% and >10% of specimens, respectively. We detected variants identified previously by targeted sequencing in EMZL from different locations (e.g. TNFAIP3 (A20) (12%), TBL1XR1 (13%), SPEN (10%), CARD11 (7%), TET2 (7%) and CREBBP (6%)). We detected mutations in KLF2 (10 mutations in 8 EMZL patients) and PTPRD (7 mutations in 7 EMZL patients) that were previously suggested to be specific for splenic and nodal MZL, respectively. We also detected variants not previously reported in EMZL, including a transcriptional factor ZEB2, LRP1B,and others. The most frequently mutated gene in our study (25% of tumors) was IGLL5. Some mutations were limited to specific locations (e.g. ZEB2 mutations seen exclusively in gastric and salivary gland EMZL), while most were observed across all anatomic locations. There was no association between specific mutations and clonal IGHV, in contrast to previous reports. Using Enrichr tool, we observed enrichment of mutations in genes belonging to the B cell receptor activation, NOTCH signaling, Wnt-beta catenin signaling, NF-kB signaling , PI3K AKT signaling, DNA repair and other pathways. Chromosomal and copy number changes were also commonly observed including previously reported trisomy of chromosomes 3 and 18. Combining DNA mutations and CN alterations, the number of genetic lesions per tumor sample in the 174 mutated genes ranged from 0 to 95, with an average load of 17 lesions per case. RNA sequencing was successful in 159 EMZL tumors from 16 distinct anatomic locations. Unsupervised clustering using all genes with a median log2-normalized gene expression value greater than 5 and a standard deviation greater than 1 (1323 genes) demonstrated that the majority of gastric EMZL with and without H. pylori infections clustered together on 2 dendrograms as did most of the samples of OAMZL. Since the clustering could be forced by organ-specific and not tumor-specific gene expression, we next focused on the expression of the 345 genes from the LM22 matrix that passed our transcriptomic row filtering. Unsupervised clustering resulted in clustering of most gastric EMZL irrespective of H. pylori positivity together in the same dendrogram branch, accompanied by few additional EMZL from other anatomic locations. Most of the EMZL samples from other locations did not show preferential co-clustering together. On comparison of gene expression between gastric and OAMZL, there was enrichment of the B-cell receptor signaling pathway, B-cell activation, B-cell naïve and B-cell memory cells, B-cell proliferation and NF-kB signaling in the latter. Immune microenvironment analysis showed a statistically significant increase in resting mast cells and decrease in M1 macrophages in gastric EMZL and increase in regulatory T cells in salivary EMZL. The broad genomic studies reported here underscore the biological similarity of EMZL across anatomical sites with the potential exceptions of gastric EMZL (regardless of H. Pylori status). These data provide valuable genomic and transcriptomic resources to inform future diagnostic and therapeutic strategies.
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence
Wu, Gongwei , Yoshida, Noriaki , Liu, Jihe , Xiong, Yuan , Heavican‐Foral, Tayla B. , Mandato, Elisa , Nelson, Geoffrey M. , Yang, Lu , Chen, Renee , Jones, M. , Roshal, Mikhail , Zhang, Yanming , Xu, Ran , Jain, Salvia , Leahy, Catharine, Jones, Kristen L. , Stevenson, Kristen E. , Galasso, Natasha, Ganesan, Nivetha , Chang, Tiffany , Wu, Wenchao, Louissaint, Abner , Debaize, Lydie , Cin, Paola Dal , Chan, Wing C. , Sui, Shannan J. Ho , Ng, Samuel Y., Chen, Chun‐Wei , Weinstock, David M. , Zhang, Xiaoyang , Xiong, Yuan , Nelson, Geoffrey M , Yang, Lu , Donovan, Katherine A , Jones, Marcus K , Zhang, Yanming , Xu, Ran , Nirmal, Ajit J , Jain, Salvia , Ganesan, Nivetha , Chang, Tiffany , Dal Cin, Paola , Ho Sui, Shannan J , Feldman, Andrew L , Horwitz, Steven M , Adelman, Karen , Fischer, Eric S , Chen, Chun-Wei , Weinstock, David M , Brown, Myles , Heavican, Tayla B., Liu, Huiyun , Yoon, Hojong , Feldman, Andrew L. , Horwitz, Steven M. , Brown, Myles

Mayo Clinic

Science Translational Medicine | September 20, 2023 | Volume: 15 | Issue: 714 | Pages: No page available

10.1126/scitranslmed.adi7244 | PMID 37729434 Get It

Gene fusions involving tumor protein p63 gene (TP63) occur in multiple T and B cell lymphomas and portend a dismal prognosis for patients. The function and mechanisms of TP63 fusions remain unclear, and there is no target therapy for patients with lymphoma harboring TP63 fusions. Here, we show that TP63 fusions act as bona fide oncogenes and are essential for fusion-positive lymphomas. Transgenic mice expressing TBL1XR1::TP63, the most common TP63 fusion, develop diverse lymphomas that recapitulate multiple human T and B cell lymphomas. Here, we identify that TP63 fusions coordinate the recruitment of two epigenetic modifying complexes, the nuclear receptor corepressor (NCoR)—histone deacetylase 3 (HDAC3) by the N-terminal TP63 fusion partner and the lysine methyltransferase 2D (KMT2D) by the C-terminal TP63 component, which are both required for fusion-dependent survival. TBL1XR1::TP63 localization at enhancers drives a unique cell state that involves up-regulation of MYC and the polycomb repressor complex 2 (PRC2) components EED and EZH2. Inhibiting EZH2 with the therapeutic agent valemetostat is highly effective at treating transgenic lymphoma murine models, xenografts, and patient-derived xenografts harboring TP63 fusions. One patient with TP63 -rearranged lymphoma showed a rapid response to valemetostat treatment. In summary, TP63 fusions link partner components that, together, coordinate multiple epigenetic complexes, resulting in therapeutic vulnerability to EZH2 inhibition.
Abstract 5755: TP63 fusions drive enhancer rewiring, lymphomagenesis, and dependence on EZH2
Wu, Gongwei , Liu, Jihe , Xiong, Yuan , Heavican‐Foral, Tayla B. , Yang, Lu , Chen, Renee , Jones, M. , Roshal, Mikhail , Zhang, Yanming , Xu, Ran , Jain, Salvia , Leahy, Catharine, Jones, Kristen L. , Stevenson, Kristen E. , Galasso, Natasha, Ganesan, Nivetha , Chang, Tiffany , Wu, Wenchao, Louissaint, Abner , Debaize, Lydie , Cin, Paola Dal , Chan, Wing Chan, Sui, Shannan Ho Sui Ho, Ng, Samuel Y., Meyerson, Mathew L., Weinstock, David M. , Yoshida, Noriaki , Zhang, Xiaoyang , Heavican, Tayla B., Liu, Huiyun, Nelson, Geoffrey M. , Donovan, Katherine A , Nirmal, Ajit J , Yoon, Hojong , Feldman, Andrew L. , Horwitz, Steven M. , Adelman, Karen , Fischer, Eric S , Chen, Chun‐Wei , Brown, Myles

Mayo Clinic

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 5755-5755

10.1158/1538-7445.am2023-5755 Get It

Abstract Recurrent chromosomal rearrangements are a hallmark of hematologic malignancies and play critical roles in pathogenesis. The TP53 analog TP63 is rearranged in 5-10% of diverse subtypes of both aggressive T- and B-cell lymphomas. Patients with TP63-rearranged lymphomas have dismal outcomes, with 5-year overall survival rates between 0-17%, depending on cohorts. The function and mechanisms of TP63 rearrangements and TP63 fusion proteins in tumorigenesis are poorly understood. As a result, attempts to treat these patients to date have been largely empiric. Thus, there is an urgent need to understand how TP63 fusions contribute to tumorigenesis and to translate the findings into novel therapeutic options for these patients. Here, we demonstrated that TP63 fusions are essential for the propagation of T-cell lymphomas (TCLs). Knockdown of TP63 fusions with specific shRNAs in TCL cell lines harboring TP63 fusions suppressed both cell growth in vitro and tumor growth in vivo. Retroviral expression of TBL1XR1-TP63, the most common TP63 fusion, conferred cytokine independence in Ba/F3 cells, consistent with its role as an oncogene. To investigate the role of TP63 fusions in T- and B-cell lymphomagenesis, we engineered a CAG-Loxp-Stop-Loxp-TBL1XR1-TP63 conditional knock-in mouse model and crossed with hCD2-Cre mice. This results in expression beginning during early lymphoid development. As observed in patients, transgenic mice developed multiple subtypes of both T- and B-cell lymphoma. To define the effects and mechanisms of TP63 fusions within T cells, we performed CRISPR scanning, transcriptomic, epigenomic, and proteomic analyses. Our data showed that domains within both the N-terminal TBL1XR1 and C-terminal TP63 portions contribute to the function of this fusion. We found that the N-terminal component of TP63 fusions interacts with components of the NCOR/SMRT complex. At the same time, the C-terminal portion of TP63 (which recapitulates the deltaN-p63 isoform expressed in some carcinomas) interacts with the enhancer modifier KMT2D and its complex members. TBL1XR1-TP63 binds to a novel distal enhancer to drive MYC expression, and thus upregulates the expression of the histone H3K27 methylase EZH2. Finally, we assessed whether EZH2 is a vulnerability of TP63-rearranged lymphomas. We found that knockdown of EZH2 in TP63-rearranged lines significantly impaired cell growth, as did treatment with the EZH2 and 1 dual inhibitor valemetostat. Valemetostat, which is now being tested in patients with lymphoma, counteracted the oncogenic effects of TP63 fusions in multiple preclinical models in vivo. Together, our results identify the TP63 fusion as a highly unique oncogenic driver in lymphomagenesis capable of recruiting multiple epigenetic modifier complexes and inducing a targetable dependence on EZH2. Citation Format: Gongwei Wu, Noriaki Yoshida, Jihe Liu, Xiaoyang Zhang, Yuan Xiong, Tayla Heavican-Foral, Huiyun Liu, Geoffrey Nelson, Lu Yang, Renee Chen, Katherine Donovan, Marcus Jones, Mikhail Roshal, Yanming Zhang, Ran Xu, Ajit Nirmal, Salvia Jain, Catharine Leahy, Kristen Jones, Kristen Stevenson, Natasha Galasso, Nivetha Ganesan, Tiffany Chang, Wen-Chao Wu, Abner Louissaint, Lydie Debaize, Hojong Yoon, Paola Dal Cin, Wing Chan Chan, Shannan Ho Sui Ho Sui, Samuel Ng, Andrew Feldman, Steven M. Horwitz, Mathew Meyerson, Karen Adelman, Eric Fischer, Chun-Wei Chen, David Weinstock, Myles Brown. TP63 fusions drive enhancer rewiring, lymphomagenesis, and dependence on EZH2. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5755.